AR070119A1 - Derivados de insulina con perfil tiempo / accion extremadamente retardado - Google Patents

Derivados de insulina con perfil tiempo / accion extremadamente retardado

Info

Publication number
AR070119A1
AR070119A1 ARP090100036A ARP090100036A AR070119A1 AR 070119 A1 AR070119 A1 AR 070119A1 AR P090100036 A ARP090100036 A AR P090100036A AR P090100036 A ARP090100036 A AR P090100036A AR 070119 A1 AR070119 A1 AR 070119A1
Authority
AR
Argentina
Prior art keywords
corresponds
glu
asp
chemical bond
lys
Prior art date
Application number
ARP090100036A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102008003566A external-priority patent/DE102008003566A1/de
Priority claimed from DE200810025007 external-priority patent/DE102008025007A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR070119A1 publication Critical patent/AR070119A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP090100036A 2008-01-09 2009-01-07 Derivados de insulina con perfil tiempo / accion extremadamente retardado AR070119A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008003566A DE102008003566A1 (de) 2008-01-09 2008-01-09 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE200810025007 DE102008025007A1 (de) 2008-05-24 2008-05-24 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil

Publications (1)

Publication Number Publication Date
AR070119A1 true AR070119A1 (es) 2010-03-17

Family

ID=40473425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100036A AR070119A1 (es) 2008-01-09 2009-01-07 Derivados de insulina con perfil tiempo / accion extremadamente retardado

Country Status (20)

Country Link
US (1) US8633156B2 (https=)
EP (1) EP2229406B1 (https=)
JP (1) JP5695909B2 (https=)
KR (1) KR20100111683A (https=)
CN (1) CN101970476B (https=)
AR (1) AR070119A1 (https=)
AU (1) AU2009203810B2 (https=)
BR (1) BRPI0907119A2 (https=)
CA (1) CA2711752A1 (https=)
CL (1) CL2009000018A1 (https=)
CO (1) CO6290770A2 (https=)
IL (1) IL206843A0 (https=)
MA (1) MA31997B1 (https=)
NZ (1) NZ586589A (https=)
PA (1) PA8811501A1 (https=)
PE (1) PE20091305A1 (https=)
TW (1) TWI433681B (https=)
UY (1) UY31597A1 (https=)
WO (1) WO2009087082A2 (https=)
ZA (1) ZA201003927B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
MY152979A (en) * 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
IN2015DN00544A (https=) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
BR112016015851A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
CR20160376A (es) * 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN110615836B (zh) * 2018-06-20 2022-09-13 鲁南制药集团股份有限公司 一种利拉鲁肽的固相合成方法
CN115702880B (zh) * 2021-08-12 2023-11-03 山东新时代药业有限公司 一种重组甘精胰岛素注射液及其制备工艺

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
IE62879B1 (en) 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
GR1005153B (el) 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
JP2002509081A (ja) 1998-03-12 2002-03-26 バイオポア アイエヌシー． 精子−卵結合に関与する分子の受精前の作用の増強
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE60233722D1 (de) * 2001-04-02 2009-10-29 Novo Nordisk As Insulinvorstufen und verfahren zu deren herstellung
CZ2004710A3 (cs) * 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
EP1620465A2 (en) 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
CN1780854A (zh) * 2003-04-29 2006-05-31 伊莱利利公司 具有延长时间作用的胰岛素类似物
WO2006091231A2 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
JP2008513384A (ja) 2004-09-17 2008-05-01 ノボ ノルディスク アクティーゼルスカブ インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
AU2006291780B2 (en) 2005-09-14 2011-12-08 F. Hoffmann-La Roche Ag Cleavage of precursors of insulins by a variant of trypsin
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US9445113B2 (en) 2006-01-10 2016-09-13 Thomson Licensing Methods and apparatus for parallel implementations of 4:4:4 coding
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile

Also Published As

Publication number Publication date
US20110173722A1 (en) 2011-07-14
UY31597A1 (es) 2009-08-31
MA31997B1 (fr) 2011-01-03
KR20100111683A (ko) 2010-10-15
PE20091305A1 (es) 2009-09-26
CN101970476B (zh) 2014-08-27
US8633156B2 (en) 2014-01-21
HK1148542A1 (en) 2011-09-09
CL2009000018A1 (es) 2009-06-05
WO2009087082A2 (de) 2009-07-16
TW200942257A (en) 2009-10-16
ZA201003927B (en) 2011-04-28
AU2009203810B2 (en) 2013-07-25
BRPI0907119A2 (pt) 2015-07-14
CO6290770A2 (es) 2011-06-20
IL206843A0 (en) 2010-12-30
EP2229406A2 (de) 2010-09-22
JP2011509269A (ja) 2011-03-24
EP2229406B1 (de) 2015-04-22
CA2711752A1 (en) 2009-07-16
JP5695909B2 (ja) 2015-04-08
AU2009203810A1 (en) 2009-07-16
WO2009087082A3 (de) 2009-09-24
TWI433681B (zh) 2014-04-11
PA8811501A1 (es) 2009-09-17
CN101970476A (zh) 2011-02-09
NZ586589A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
AR070119A1 (es) Derivados de insulina con perfil tiempo / accion extremadamente retardado
ECSP10010333A (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
ES2558842T3 (es) Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
AR105616A1 (es) Proteínas de fusión
AR077455A1 (es) Preparaciones insulinicas de accion lenta
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
CO6480996A2 (es) Preparaciones insulinicas que comprenden metionina
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
AR094180A1 (es) Derivados de exendina-4
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
JP2013518115A5 (https=)
RU2011134596A (ru) Аналоги оксинтомодулина
RU2012153753A (ru) Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
HRP20240135T1 (hr) Fgf21 mutanti i njihove upotrebe
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
PE20200514A1 (es) Compuestos de mic-1 y usos de estos
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
AR088727A1 (es) Peptidos ciclicos con actividad antineoplasica y antiangiogenica
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
WO2009038729A3 (en) Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada
MX2015009399A (es) Analogos de insulina truncados en n-terminal.

Legal Events

Date Code Title Description
FB Suspension of granting procedure